Understanding Type 1 Diabetes and the Immune System
Type 1 diabetes (T1D) represents one of the most challenging autoimmune conditions affecting millions of people worldwide. This chronic disease is characterized by the selective destruction of pancreatic insulin-producing beta cells, primarily mediated by CD4+ and CD8+ T cells. Unlike type 2 diabetes, which develops gradually due to insulin resistance, type 1 diabetes occurs when the body's own immune system mistakenly identifies beta cells as foreign invaders and launches a sustained attack against them.
The progression of type 1 diabetes follows a predictable pattern through distinct stages. Stage 1 is characterized by the appearance of autoantibodies, followed by stage 2 with dysglycemia, where metabolic responses to a glucose load are impaired but other metabolic indexes remain normal and insulin treatment is not needed. By the time patients reach stage 3, they require lifelong insulin therapy to maintain glucose homeostasis and prevent serious complications. Understanding this progression has opened new avenues for therapeutic intervention, particularly in the earlier stages before significant beta cell loss occurs.
The autoimmune attack in T1D involves multiple components of the immune system working in concert. Autoantibodies target beta cell antigens such as insulin, glutamic acid decarboxylase (GAD65), and islet antigen-2 (IA-2). This complex interplay between different immune cells and antibodies makes treating type 1 diabetes particularly challenging, as interventions must be carefully designed to modulate the immune response without causing widespread immunosuppression that could leave patients vulnerable to infections.
The Rationale Behind Immune Cell Depletion Strategies
Immune cell depletion represents a paradigm shift in how we approach type 1 diabetes treatment. Rather than simply managing blood sugar levels with exogenous insulin, these strategies aim to address the root cause of the disease by targeting the immune cells responsible for destroying beta cells. The goal is to halt or significantly slow disease progression, preserve remaining beta cell function, and potentially delay or prevent the need for insulin therapy.
In recent years, there has been significant advancement in immune-targeted pharmacotherapy to halt the natural progression of T1D, with immune-targeted intervention aiming to alter the underlying pathogenesis by targeting different aspects of the immune system. This approach represents a fundamental change from treating symptoms to addressing the underlying disease mechanism.
The concept of immune cell depletion in T1D is based on decades of research in animal models and human clinical trials. Early studies demonstrated that selectively removing or modifying certain immune cell populations could prevent or reverse diabetes in animal models. These promising preclinical results paved the way for human trials, which have now demonstrated that carefully targeted immune interventions can preserve beta cell function and delay disease progression in people at risk for or newly diagnosed with type 1 diabetes.
One of the key advantages of immune cell depletion strategies is their potential to provide long-lasting benefits from relatively short treatment courses. Unlike daily insulin therapy, which patients must continue for life, some immune-modulating therapies require only brief treatment periods yet can provide benefits lasting months or even years. This makes them particularly attractive for early intervention in individuals identified as being at high risk for developing clinical diabetes.
Monoclonal Antibody Therapies: Leading the Charge
Teplizumab: The First FDA-Approved Disease-Modifying Therapy
Teplizumab, the first immunotherapy treatment to delay the onset of clinical type 1 diabetes, has been approved by the US Food and Drug Administration. This landmark approval in 2022 marked a historic moment in diabetes care, representing the first disease-modifying therapy for any autoimmune condition approved before clinical onset of disease.
Teplizumab is a humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the ε chain of CD3, with its complementarity-determining region derived from ortho kung T3 (OKT3), the first monoclonal antibody licensed for human use for acute solid graft rejection. The drug was specifically engineered to minimize side effects while maintaining therapeutic efficacy. Unlike its predecessor OKT3, which caused severe cytokine release syndrome, teplizumab has been modified to reduce Fc-receptor binding, resulting in a much more tolerable safety profile.
The mechanism of action of teplizumab is multifaceted and sophisticated. Teplizumab mitigates autoimmune destruction of pancreatic β-cells through increases in proportion of regulatory T cells and exhausts CD8+ T cells and CD4+ T-cell in peripheral blood, leading to deactivation of autoreactive T lymphocytes, with these effects occurring through various pathways including apoptosis in activated T cells through signaling via TGF-β and TNF-α. This selective modulation of the immune system allows teplizumab to reduce autoimmune activity without causing broad immunosuppression.
Clinical trial results for teplizumab have been impressive and consistent across multiple studies. Over a median follow up period of 51 months, 43% of patients in Teplizumab group progressed to stage 3 of T1D, compared to 72% in the placebo group, with the median time to diagnosis being 48.4 months for those receiving teplizumab and 24.4 months for the placebo group. Even more remarkably, in an extension trial with a median follow-up of 76.9 months, the median time to diagnosis was 59.6 months for the teplizumab group and 27.1 months for the placebo group, with 50% of those treated with teplizumab remaining free of diabetes, in contrast to 22% of those receiving the placebo.
Sanofi's TZIELD is a prescription immunotherapy that delays the onset of stage 3 T1D in adults and children (8+ years of age) with stage 2 T1D, targeting the immune system to slow the destruction of insulin-producing beta cells, with a single 2-week course resulting in a median of 4 years before the onset of insulin-dependent type 1 diabetes, compared to 2 years with placebo. This represents a doubling of the time before patients require insulin therapy, providing valuable years of life without the burden of daily insulin injections and intensive diabetes management.
Recent developments have expanded the potential use of teplizumab even further. The US Food and Drug Administration has approved the supplemental biologic license application for Tzield, expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes in patients diagnosed with stage 2 T1D, with approval granted under a priority review process and supported by one-year data from the PETITE-T1D phase 4 study. This expansion means that even very young children identified as being at high risk can now benefit from disease-modifying therapy.
The safety profile of teplizumab has been well-characterized through extensive clinical trials. The most frequently reported adverse effects in more than 10% of participants included lymphopenia (73%), rash (36%), leukopenia (21%), and headache (11%), with cytokine release syndrome affecting 5% of patients receiving teplizumab compared with 0.8% in the placebo group. Most adverse events occur during the initial treatment course and resolve without intervention, making the therapy generally well-tolerated.
Rituximab and B-Cell Depletion
While T cells have received the most attention in type 1 diabetes research, B cells also play a crucial role in the autoimmune process. B cells not only produce autoantibodies but also serve as antigen-presenting cells that activate autoreactive T cells. This has led researchers to investigate whether depleting B cells could slow or prevent type 1 diabetes progression.
A study using Rituximab, an anti-CD20 antibody, showed transient preservation of beta cell function in newly diagnosed T1D patients, with Rituximab-treated patients exhibiting higher C-peptide levels compared to the placebo group after one year, indicating a delay in disease progression. Rituximab works by targeting CD20, a protein found on the surface of B cells, leading to their depletion from circulation.
While rituximab showed promise in early trials, its effects were ultimately found to be temporary. The preservation of beta cell function observed in the first year of treatment diminished over time, and by two years, the differences between treated and placebo groups had largely disappeared. This suggests that B-cell depletion alone may not be sufficient to provide long-lasting disease modification in type 1 diabetes.
However, research into B-cell targeting therapies continues, with scientists exploring combination approaches that might enhance efficacy. A study discussed the combination of Rituximab with proinsulin DNA vaccine in NOD mice, which aimed to induce immune tolerance, showing that this combination could enhance the regulatory T cell function and reduce the effector cell load, offering synergistic protection against T1D and suggesting potential for combination therapies in enhancing the efficacy of Rituximab in clinical settings.
Anti-Thymocyte Globulin (ATG)
Anti-thymocyte globulin represents another approach to immune cell depletion in type 1 diabetes. ATG is a polyclonal antibody preparation that targets multiple antigens on T cells, leading to their depletion. Unlike monoclonal antibodies that target a single specific protein, ATG's polyclonal nature allows it to affect T cells through multiple mechanisms.
In the TrialNet ATG-granulocyte colony-stimulating factor study, low-dose ATG (2.5 mg/kg) or low-dose ATG with pegylated G-CSF were studied in recent onset T1D patients, with authors reporting significant HbA1c reduction and slowing of c-peptide decline after 1 year of follow-up in the low-dose ATG group without any extra benefit with the addition of GCSF. These results suggested that carefully dosed ATG could preserve beta cell function in newly diagnosed patients.
The mechanism by which ATG preserves beta cell function appears to involve selective depletion of effector T cells while relatively sparing regulatory T cells. This creates a more favorable immune environment that is less hostile to remaining beta cells. However, ATG therapy requires careful monitoring due to the risk of over-immunosuppression and potential side effects.
Combination Immunotherapy Approaches
Recognizing that type 1 diabetes involves multiple immune pathways, researchers are increasingly exploring combination therapies that target different aspects of the autoimmune response simultaneously. These approaches aim to achieve synergistic effects that might be more powerful and longer-lasting than single-agent therapies.
In a phase 2, multicenter, parallel-group, placebo-controlled RCT, 308 T1D patients were randomized to four arms – anti-IL-21 only, liraglutide only, combined anti-IL-21 with liraglutide, or placebo, with the decline of post-mixed meal tolerance test c-peptide level at 52 weeks being significantly smaller in the combined group in comparison to the placebo. This demonstrates the potential power of combination approaches, as neither agent alone showed significant benefit, but together they preserved beta cell function.
The rationale for combination therapy is compelling. By targeting multiple immune pathways simultaneously, these approaches may be able to more completely suppress the autoimmune attack on beta cells. Additionally, using lower doses of multiple agents may reduce side effects compared to higher doses of single agents, while still achieving therapeutic benefit.
Advanced Cell Therapy Approaches
CAR-T Cell Therapy for Type 1 Diabetes
Chimeric Antigen Receptor (CAR) T-cell therapy, which has revolutionized cancer treatment, is now being adapted for autoimmune diseases including type 1 diabetes. Novel approaches, such as Chimeric Antigen Receptor (CAR)–Tregs therapy and JAK-STAT pathway inhibition, represent exciting areas of ongoing research. This cutting-edge approach involves engineering a patient's own immune cells to have specific therapeutic properties.
Ferreira specializes in modifying the immune system using chimeric antigen receptors, or CARs, with these engineered receptors helping guide regulatory T cells, known as Tregs, to specific targets in the body, as Tregs play an essential role in keeping immune responses under control and preventing excessive damage, including the autoimmune attack seen in T1D. By directing regulatory T cells specifically to the pancreas, CAR-Treg therapy could provide localized immune suppression exactly where it's needed, without affecting immune function throughout the rest of the body.
Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with custom-engineered immune cells that protect them, with the goal being to stop the immune system from destroying transplanted cells without using immunosuppressive drugs, backed by $1 million in funding. This innovative approach could potentially solve two problems at once: replacing lost beta cells while simultaneously protecting them from autoimmune attack.
The advantage of CAR-Treg therapy is its specificity. Traditional immunosuppressive drugs affect the entire immune system, increasing infection risk. In contrast, CAR-Tregs can be designed to act only at the site of autoimmune activity, leaving the rest of the immune system intact to fight infections and perform other protective functions. This represents a major advance in precision medicine for autoimmune diseases.
Stem Cell Transplantation and Immune Reset
One of the most ambitious approaches to treating type 1 diabetes involves completely resetting the immune system through stem cell transplantation. A combination blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely prevented or cured Type 1 diabetes in mice, with transplanting blood stem cells resulting in an immune system made up of cells from both the donor and the recipient and preventing development of Type 1 diabetes in 19 out of 19 animals.
This approach creates what researchers call a "hybrid immune system" that contains cells from both the donor and recipient. Researchers at Stanford found a way to cure or prevent Type 1 diabetes in mice using a combined blood stem cell and islet cell transplant, with the procedure creating a hybrid immune system that stops autoimmune attacks and eliminates the need for immune-suppressing drugs, using tools already common in clinical practice. The hybrid immune system appears to establish immune tolerance, preventing the autoimmune attack on beta cells while maintaining normal immune function against pathogens.
What makes this approach particularly promising is that it has been refined to use much gentler conditioning regimens than traditional bone marrow transplantation. The April study incorporated two additional drug agents that target and deplete stem cells in the recipient animal's bone marrow, allowing researchers to significantly reduce the radiation dose required for successful transplantation to 10 cGy, compared to a full bone marrow transplant which typically requires a dose of around 1,200 cGy. This dramatic reduction in radiation exposure makes the approach much safer and more feasible for clinical translation.
Stem cell therapies, particularly using mesenchymal stem cells (MSCs) and autologous hematopoietic stem cells (HSCs), demonstrate potential in immune modulation and beta cell regeneration. These therapies work through multiple mechanisms, including secreting factors that promote beta cell survival, modulating immune responses, and potentially even differentiating into insulin-producing cells themselves.
Gene Editing and Hypoimmune Cell Technologies
CRISPR-Based Approaches
Gene editing technologies, particularly CRISPR-Cas9, are opening new frontiers in type 1 diabetes treatment. These powerful tools allow scientists to make precise changes to the DNA of cells, potentially creating beta cells that are invisible to the autoimmune system or engineering immune cells that won't attack the pancreas.
One promising application of gene editing is the creation of "hypoimmune" beta cells. While significant challenges remain, including immune compatibility and graft durability, advancements in stem cell research offer a promising future, with the development of hypoimmune stem cell therapies representing a major milestone in overcoming immune rejection. These cells are engineered to lack the surface proteins that the immune system uses to identify them as targets, potentially allowing them to survive even in the presence of ongoing autoimmunity.
Several biotechnology companies are actively developing gene-edited cell therapies for type 1 diabetes. Several biotechnology and pharmaceutical companies, including Vertex, CRISPR Therapeutics, Seraxis, and Throne Biotechnologies, are actively conducting clinical trials to assess the safety and efficacy of stem cell-based therapies for T1DM. These trials represent the cutting edge of diabetes research and could potentially lead to functional cures for the disease.
The gene editing approach offers several potential advantages. First, it could eliminate the need for immunosuppressive drugs, which carry significant risks and side effects. Second, gene-edited cells could potentially be produced in large quantities from a single donor, creating an "off-the-shelf" therapy that doesn't require finding matched donors. Third, the cells could be engineered to have enhanced function or survival characteristics beyond what natural beta cells possess.
Vertex's Stem Cell-Derived Islet Therapies
Vertex Pharmaceuticals has emerged as a leader in developing stem cell-derived therapies for type 1 diabetes. Zimislecel (VX-880) is an investigational, stem cell-derived, islet cell therapy that restores the body's ability to produce insulin by replacing destroyed pancreatic cells with lab-grown cells that are infused into the liver, has been granted Fast Track designations from the U.S. Food and Drug Administration, with 2025 clinical trials showing that participants with severe T1D could achieve insulin independence after 1 year.
The islet cell therapy, called zimislecel, is produced by Vertex Pharmaceuticals and was sent to UCSF Health as part of a phase 3 clinical trial, with the islet cells being infused into the hepatic portal vein and disbursed in the liver as they establish their own blood supply and begin to make insulin. This approach has shown remarkable success in early trials, with some patients achieving complete insulin independence.
However, current versions of these therapies still require immunosuppression to prevent rejection. The therapy does require ongoing immunosuppression to prevent islet cell rejection. This represents a significant limitation, as immunosuppressive drugs carry risks of infection, cancer, and other complications. To address this, Vertex and other companies are developing next-generation therapies using gene-edited, hypoimmune cells that could potentially function without immunosuppression.
On March 28, 2025, Vertex Pharmaceuticals announced the discontinuation of VX-264 clinical trial as the efficacy data did not result in the required levels of insulin production, while Zimislecel (formerly VX-880) remains in development and is on track to complete enrolment in the first half of 2025, with likely global regulatory submissions in 2026. Despite setbacks with some programs, the field continues to advance rapidly, with multiple approaches being tested simultaneously.
Nanoparticle-Based Delivery Systems
Nanoparticle technology represents an innovative approach to delivering immune-modulating therapies specifically to the cells and tissues where they're needed. These microscopic particles can be engineered to carry drugs, antigens, or other therapeutic agents directly to target cells, potentially increasing efficacy while reducing side effects.
The advantage of nanoparticle delivery systems is their ability to achieve targeted delivery with minimal systemic exposure. Traditional immunosuppressive drugs affect the entire body, but nanoparticles can be designed to release their cargo only in specific locations or in response to specific triggers. For example, nanoparticles could be engineered to release immune-modulating drugs only in the pancreatic lymph nodes, where autoreactive T cells are activated, or directly in the pancreas where beta cells are located.
Several types of nanoparticles are being explored for type 1 diabetes therapy. Biodegradable polymer nanoparticles can encapsulate drugs or antigens and release them slowly over time, providing sustained therapeutic effects from a single dose. Lipid nanoparticles, similar to those used in some COVID-19 vaccines, can deliver genetic material to cells to modify their function. Gold nanoparticles can be used for both drug delivery and as imaging agents to track where therapies are going in the body.
One particularly promising application of nanoparticle technology is in antigen-specific immunotherapy. Nanoparticles can be loaded with beta cell antigens and designed to deliver them to immune cells in a way that promotes tolerance rather than activation. This could potentially "re-educate" the immune system to stop attacking beta cells without broadly suppressing immune function.
Research has shown that nanoparticles can also be used to deliver regulatory signals that promote the development of regulatory T cells. By packaging specific combinations of cytokines, antigens, and other factors into nanoparticles, researchers can create microenvironments that favor the development of immune tolerance. This approach could potentially be combined with other therapies to enhance their effectiveness.
Antigen-Specific Tolerance Induction
While immune cell depletion strategies aim to reduce or eliminate autoreactive immune cells, antigen-specific tolerance induction takes a different approach: teaching the immune system to tolerate beta cell antigens without attacking them. This strategy is appealing because it could potentially stop the autoimmune attack without causing broad immunosuppression.
The immunotherapy can either antagonize the immune mediators like T cells, B cells or cytokines (antibody-based therapy), or reinduce self-tolerance to pancreatic β cells (antigen-based therapy) or stem-cell treatment. Antigen-based approaches aim to restore the natural tolerance mechanisms that failed in type 1 diabetes, potentially providing a more physiologic solution to the problem.
Several beta cell antigens have been tested as targets for tolerance induction, including insulin, glutamic acid decarboxylase (GAD65), and heat shock proteins. The idea is to administer these antigens in a way that promotes tolerance rather than immune activation. This might involve giving them orally, nasally, or in combination with immune-modulating agents that favor regulatory T cell development.
Antigen-dependent strategies focus on inducing immune tolerance to specific beta cell antigens, with mixed results from clinical trials involving autoantigen vaccines like GAD65. While the concept is sound, achieving reliable tolerance induction in humans has proven challenging. The immune system in people with established type 1 diabetes appears to be less responsive to tolerance-inducing signals than in animal models or in people at earlier disease stages.
Despite these challenges, research in antigen-specific tolerance continues, with newer approaches showing promise. These include using nanoparticles to deliver antigens in tolerogenic forms, combining antigens with specific immune-modulating drugs, and targeting antigens to specific immune cell populations that are more likely to promote tolerance. Some researchers are also exploring whether tolerance induction might be more effective in combination with other therapies, such as immune cell depletion followed by tolerance induction to prevent disease recurrence.
Clinical Challenges and Considerations
Balancing Efficacy and Safety
One of the greatest challenges in developing immune cell depletion strategies for type 1 diabetes is achieving the right balance between efficacy and safety. Treatments must be powerful enough to significantly impact the autoimmune process, but not so aggressive that they cause dangerous immunosuppression or other serious side effects.
The experience with teplizumab illustrates this balance well. The drug causes transient lymphopenia and other immune changes, but these are generally self-limited and resolve without intervention. More serious side effects like cytokine release syndrome occur in only a small percentage of patients and can be managed with appropriate monitoring and supportive care. This safety profile has been deemed acceptable given the significant benefits the drug provides in delaying disease progression.
However, not all immune-modulating therapies have achieved this favorable risk-benefit balance. Some approaches that showed promise in animal models caused unacceptable side effects in humans. Others were safe but insufficiently effective to justify their use. Finding therapies that are both safe and effective enough to change clinical practice remains a major challenge in the field.
The challenge is particularly acute for preventive therapies used in people who don't yet have clinical diabetes. The bar for safety is necessarily higher when treating people who are currently healthy, even if they're at high risk for future disease. This has led to careful dose-finding studies and extensive safety monitoring in clinical trials of disease-modifying therapies for stage 2 type 1 diabetes.
Identifying the Right Patients and Timing
Another critical challenge is determining which patients should receive immune-modulating therapies and when. Type 1 diabetes is a heterogeneous disease, with different patients progressing at different rates and responding differently to treatments. Identifying biomarkers that can predict who will benefit most from specific therapies is an active area of research.
The staging system for type 1 diabetes has been crucial in enabling earlier intervention. By identifying people in stage 2 who have autoantibodies and dysglycemia but haven't yet developed clinical diabetes, clinicians can now offer disease-modifying therapy before significant beta cell loss has occurred. This represents a major advance, as preserving beta cells is much easier than trying to regenerate them once they're lost.
However, not everyone in stage 2 progresses to stage 3 at the same rate. Some people remain in stage 2 for many years, while others progress rapidly. Developing better predictive models to identify who needs treatment most urgently is an important goal. This would allow clinicians to target therapies to those most likely to benefit while sparing others from unnecessary treatment and potential side effects.
Timing of intervention is also crucial. Evidence suggests that immune-modulating therapies may be most effective when significant beta cell mass remains. Once most beta cells are destroyed, stopping the autoimmune attack may be less beneficial. This argues for screening programs to identify at-risk individuals early, before they develop clinical diabetes, so that disease-modifying therapies can be offered at the optimal time.
Long-Term Efficacy and Durability
A key question for all immune cell depletion strategies is how long their benefits last. Some therapies provide only transient effects, with disease progression resuming once treatment is stopped. Others appear to provide more durable benefits, potentially through inducing lasting changes in immune regulation.
The long-term follow-up data from teplizumab trials is encouraging in this regard, showing sustained benefits years after treatment. However, even with teplizumab, most patients eventually progress to clinical diabetes, just at a slower rate than untreated individuals. This raises the question of whether repeated treatment courses might be beneficial, or whether combination approaches might provide more durable disease modification.
Understanding the mechanisms underlying durable versus transient responses is crucial for developing better therapies. Some evidence suggests that treatments that successfully induce regulatory T cells or other tolerance mechanisms may provide longer-lasting benefits than those that simply deplete effector cells. This is driving research into combination approaches that pair immune cell depletion with tolerance induction strategies.
Cost and Accessibility
The cost of advanced immune cell depletion therapies represents a significant barrier to widespread adoption. Monoclonal antibodies like teplizumab are expensive to manufacture, and treatments requiring multiple infusions or specialized administration add to the overall cost. Cell therapies and gene-edited products are even more expensive, potentially costing hundreds of thousands of dollars per patient.
However, economic analyses suggest that disease-modifying therapies may be cost-effective in the long run by delaying or preventing the need for lifelong insulin therapy and reducing diabetes complications. The lifetime cost of managing type 1 diabetes is substantial, including not just insulin and supplies but also the costs of treating complications like kidney disease, cardiovascular disease, and vision problems. Therapies that can delay disease onset or preserve beta cell function could potentially save money over time while improving quality of life.
Ensuring equitable access to these therapies is another important consideration. Screening programs to identify people at risk for type 1 diabetes are not yet widely available, meaning many people who could benefit from disease-modifying therapies may not be identified in time. Expanding screening and ensuring that all eligible patients have access to approved therapies regardless of socioeconomic status will be important as the field advances.
Future Directions and Emerging Strategies
Personalized Medicine Approaches
The future of type 1 diabetes treatment likely lies in personalized medicine approaches that tailor therapies to individual patients based on their specific disease characteristics, genetic background, and immune profiles. This comprehensive overview underscores the necessity of personalized therapeutic approaches and continued research to optimize existing therapies and explore new targets, ultimately aiming to improve outcomes and achieve a potential cure for T1D.
Advances in immunophenotyping and genomics are making it possible to characterize each patient's disease in unprecedented detail. This information could be used to predict which therapies are most likely to work for specific individuals, avoiding the trial-and-error approach that has characterized much of medicine historically. For example, patients with certain genetic variants or immune profiles might respond better to T-cell-directed therapies, while others might benefit more from B-cell depletion or antigen-specific approaches.
Biomarkers that can predict treatment response are being actively sought. These might include specific patterns of autoantibodies, particular immune cell populations, genetic markers, or metabolic parameters. Identifying such biomarkers would allow clinicians to select the most appropriate therapy for each patient and potentially adjust treatment based on early indicators of response or non-response.
Combination Therapy Strategies
As our understanding of type 1 diabetes pathogenesis deepens, it's becoming clear that combination approaches targeting multiple pathways simultaneously may be necessary to achieve optimal disease modification. Just as combination therapy has become standard in treating cancer and HIV, the future of type 1 diabetes treatment may involve carefully designed combinations of immune-modulating agents.
Potential combination strategies include pairing immune cell depletion with tolerance induction, combining different types of immune-modulating antibodies, or adding beta cell protective agents to immune therapies. Combining treatments may prolong and enhance responses in those at risk for type 1 diabetes, and replacing the insulin-producing cells that have been destroyed—even with stem cell-derived beta cells, together with teplizumab, may be an effective combination.
The challenge with combination approaches is determining the optimal combinations, doses, and timing. Each additional agent adds complexity and potential for side effects, so combinations must be carefully designed and tested. However, the potential for synergistic effects that could provide more complete and durable disease modification makes this an exciting area of research.
Integration with Beta Cell Replacement
Perhaps the most exciting future direction is the integration of immune-modulating therapies with beta cell replacement strategies. The combination of stopping the autoimmune attack while simultaneously replacing lost beta cells could potentially provide a functional cure for type 1 diabetes.
Scientists are pairing stem cell–derived insulin-producing cells with engineered immune "bodyguards" to protect them from autoimmune attack, with the strategy aiming to free people with type 1 diabetes from daily insulin injections and move closer to a real cure. This integrated approach addresses both the cause of the disease (autoimmunity) and its consequence (beta cell loss).
Several research groups are working on such integrated approaches. Some are using immune-modulating therapies to create a window of opportunity for beta cell transplantation, with the idea that the transplanted cells will be protected during the critical early period when they're most vulnerable. Others are developing gene-edited beta cells that are inherently resistant to autoimmune attack, which could potentially survive even without aggressive immunosuppression.
The ultimate goal is a one-time treatment that both stops the autoimmune process and restores normal insulin production, freeing patients from the burden of diabetes management. While this remains aspirational, the rapid pace of progress in both immunotherapy and cell therapy suggests it may be achievable in the coming years.
Prevention in High-Risk Individuals
With the approval of teplizumab for stage 2 type 1 diabetes, attention is increasingly turning to even earlier intervention. Could immune-modulating therapies prevent type 1 diabetes entirely if given early enough? This question is driving research into treating people in stage 1, who have autoantibodies but no metabolic abnormalities yet.
The rationale for such early intervention is compelling. At stage 1, beta cell mass is still largely intact, and the autoimmune process may be easier to stop before it gains momentum. However, the ethical and practical challenges are significant. Most people in stage 1 will eventually develop diabetes, but not all, and the timeline is highly variable. Treating everyone in stage 1 would mean giving therapy to some people who might never have developed clinical diabetes, exposing them to potential side effects for uncertain benefit.
Better risk stratification tools are needed to identify which stage 1 individuals are most likely to progress rapidly and would benefit most from early intervention. Genetic markers, immune profiles, and metabolic parameters are all being studied as potential predictors. As these tools improve, it may become possible to offer truly preventive therapy to those at highest risk.
The Role of Screening and Early Detection
The success of disease-modifying therapies depends critically on identifying people who could benefit from them. This has led to increased emphasis on screening for type 1 diabetes risk, particularly in children with family members who have the disease.
Breakthrough T1D's Vice President of Medical Affairs spearheaded an effort to establish a consensus on T1D screening guidance, with these guidelines pushing for population-level T1D screening and providing guidance for HCPs to effectively integrate T1D screening into their clinics. Such screening programs could identify people in early disease stages when interventions are most likely to be effective.
Screening typically involves testing for autoantibodies against beta cell antigens. People with multiple autoantibodies are at high risk for developing type 1 diabetes and may be candidates for disease-modifying therapy. Some programs also include genetic testing, as certain HLA types are strongly associated with type 1 diabetes risk.
The challenge is implementing screening programs at scale. Testing everyone would be expensive and impractical, so most current programs focus on high-risk groups like relatives of people with type 1 diabetes. However, most people who develop type 1 diabetes don't have an affected family member, so this approach misses many cases. Developing cost-effective strategies for broader screening is an important goal.
Education is also crucial. Many healthcare providers and families are not aware of the staging system for type 1 diabetes or the availability of disease-modifying therapies. Increasing awareness could lead to more people being screened and identified early enough to benefit from intervention. Patient advocacy organizations are playing a key role in this education effort.
Regulatory and Reimbursement Landscape
The regulatory approval of teplizumab marked a watershed moment, demonstrating that disease-modifying therapies for type 1 diabetes can meet regulatory standards for safety and efficacy. In November 2022, teplizumab-mzwv became the first drug approved to change the progression of autoimmunity in type 1 diabetes, representing the first drug approval for the delay of any autoimmune disease in patients before clinical onset. This precedent is paving the way for other therapies in development.
However, regulatory approval is only the first step. For therapies to reach patients, they must also be covered by insurance and healthcare systems. The high cost of many advanced therapies raises questions about reimbursement and cost-effectiveness. Payers are increasingly demanding evidence not just of clinical efficacy but also of real-world effectiveness and economic value.
Health economic studies are therefore becoming increasingly important in the development of new therapies. These studies must demonstrate that the upfront costs of disease-modifying therapies are justified by long-term savings from delayed disease onset, reduced insulin use, and fewer complications. Early analyses suggest that therapies like teplizumab may indeed be cost-effective, but more data is needed, particularly on long-term outcomes.
The regulatory pathway for cell and gene therapies presents additional challenges. These complex products don't fit neatly into traditional drug approval frameworks, requiring regulators to develop new approaches to evaluating their safety and efficacy. The FDA and other regulatory agencies are working to create clearer pathways for these innovative therapies while maintaining appropriate safety standards.
Patient Perspectives and Quality of Life
While much of the discussion around immune cell depletion strategies focuses on clinical endpoints like C-peptide levels and insulin requirements, the patient perspective is equally important. How do these therapies affect quality of life? What are patients' priorities and concerns?
For people diagnosed with stage 2 type 1 diabetes, the prospect of delaying progression to insulin dependence is enormously appealing. Years without the burden of multiple daily insulin injections, constant blood sugar monitoring, and fear of hypoglycemia represent a significant quality of life benefit. Even if these therapies don't prevent diabetes entirely, delaying its onset by several years can mean children can go through important developmental periods without the disease burden.
However, the treatments themselves can be burdensome. Teplizumab requires 14 consecutive days of intravenous infusions, which can be disruptive to work, school, and family life. Side effects, while generally manageable, can be unpleasant. Some patients may prefer to wait until they actually need insulin rather than undergo treatment while they're still feeling well.
These considerations highlight the importance of shared decision-making between patients, families, and healthcare providers. Not everyone will make the same choice about whether to pursue disease-modifying therapy, and that's appropriate. Providing clear, balanced information about the potential benefits and risks allows people to make informed decisions aligned with their values and priorities.
Patient advocacy organizations play a crucial role in supporting people through these decisions and connecting them with resources and support. They also provide valuable input to researchers and drug developers about what matters most to patients, helping to ensure that new therapies address real patient needs and priorities.
Global Perspectives and Health Equity
Type 1 diabetes is a global disease, but access to advanced therapies varies dramatically around the world. While cutting-edge immunotherapies and cell therapies are being developed and tested primarily in high-income countries, most people with type 1 diabetes live in low- and middle-income countries where even basic insulin access remains a challenge.
Ensuring that advances in immune cell depletion strategies benefit all people with type 1 diabetes, regardless of where they live or their economic circumstances, is a critical challenge. This will require not just developing effective therapies but also making them affordable and accessible globally. Generic versions of monoclonal antibodies, simplified treatment protocols that don't require specialized facilities, and technology transfer to enable local production in different regions may all be necessary.
Health equity considerations also apply within high-income countries. Racial and ethnic minorities, rural populations, and people with lower socioeconomic status often have less access to specialized diabetes care and may be less likely to be screened for type 1 diabetes risk or offered disease-modifying therapies. Addressing these disparities requires intentional effort to ensure that screening programs and treatment access reach all communities.
Research participation is another equity issue. Clinical trials of new therapies have historically underrepresented minority populations, which can limit the generalizability of results and may mean that therapies are less well-studied in some groups. Increasing diversity in clinical trials is essential to ensure that new therapies work well for all patients.
Conclusion: A New Era in Type 1 Diabetes Treatment
The field of immune cell depletion strategies for type 1 diabetes has advanced dramatically in recent years, moving from theoretical concepts to approved therapies that are changing patients' lives. There has been a paradigm shift in research on type 1 diabetes in the last decade, from managing the consequences of β cell death to prevention of β cell destruction, with immunotherapy showing the path forward and recent regulatory approval of teplizumab in stage 2 of T1D marking the first significant advance in research of immunotherapy.
The approval of teplizumab represents a historic milestone, proving that it's possible to modify the course of type 1 diabetes and delay its progression. This success is spurring investment and research into even more advanced approaches, from CAR-T cell therapies to gene-edited beta cells to sophisticated combination strategies. The pace of innovation is accelerating, with multiple promising therapies in clinical trials and new approaches emerging from laboratories around the world.
Looking ahead, the goal is not just to delay type 1 diabetes but to prevent it entirely or even cure it in people who already have the disease. While this remains challenging, it no longer seems impossible. The combination of immune-modulating therapies to stop the autoimmune attack and cell-based therapies to replace lost beta cells could potentially provide a functional cure, freeing people from the burden of diabetes management.
However, significant challenges remain. Ensuring that these advanced therapies are safe, effective, affordable, and accessible to all who need them will require continued effort from researchers, clinicians, regulators, payers, and patient advocates. Developing better biomarkers to predict who will benefit most from specific therapies, optimizing combination approaches, and extending benefits to earlier disease stages are all active areas of research.
For patients and families affected by type 1 diabetes, these advances offer genuine hope. While we're not yet at the point of a universal cure, we're making steady progress toward that goal. Each new therapy approved, each clinical trial completed, and each mechanism understood brings us closer to a world where type 1 diabetes can be prevented or cured rather than simply managed.
The journey from the discovery of insulin a century ago to today's disease-modifying immunotherapies represents remarkable scientific progress. The next decade promises to be equally transformative, with innovations in immune cell depletion, cell therapy, gene editing, and personalized medicine converging to fundamentally change how we approach type 1 diabetes. For the millions of people living with or at risk for this disease, and for the researchers and clinicians dedicated to helping them, this is truly an exciting time.
To learn more about type 1 diabetes research and treatment advances, visit the Breakthrough T1D website, explore resources at the American Diabetes Association, or check the latest clinical trials at ClinicalTrials.gov. For information about screening and early detection, the Type 1 Diabetes TrialNet offers free screening for relatives of people with type 1 diabetes. Staying informed about these rapidly advancing therapies empowers patients and families to make the best decisions for their health and future.